11:30 AM EST, 12/03/2024 (MT Newswires) -- Pacira BioSciences ( PCRX ) said Tuesday it obtained a patent from the US Patent and Trademark Office protecting the chemical composition of its non-opioid pain treatment Exparel into July 2044.

Pacira said it will submit the patent for listing in the Food and Drug Administration's Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations.

The company said it intends to file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals and its US distributor, Fresenius Kabi USA.

Jiangsu Hengrui Pharmaceuticals and Fresenius Kabi USA didn't immediately respond to requests for comment from MT Newswires.

Pacira shares were down 2.7% in recent Tuesday trading.

Price: 17.33, Change: -0.48, Percent Change: -2.72